Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Published Date: 18 Feb 2023

Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Through Consolidation Durvalumab, Limited-Stage SCLC Receives a New Standard of Care.

2.

Breast density changes over time are associated with an increased risk of cancer.

3.

New research demonstrates a method for screening people at high risk for pancreatic cancer.

4.

Study sheds light on challenges for women of color after breast cancer surgery

5.

Optimizing Sequencing of BCMA-Directed Therapies in Myeloma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot